Skip to main content
. 2017 May 29;4:2054358117709496. doi: 10.1177/2054358117709496

Table 1.

Prevalence of the Use of Second-Line Agents (N = 78).

Second-line agent used No. of patients received,a n (%)
Cyclophosphamide 36 (46.2)
Levamisole 14 (17.9)
Cyclosporine 13 (16.7)
Rituximab 10 (12.8)
Pulse methylprednisolone 5 (6.4)
Tacrolimus 5 (6.4)
Mycophenolate mofetil 2 (2.6)
Total exposed 43 (55.1)
a

Data for 3 patients were not available.